Dr. Yan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
301 Tyson Ave
Paris, TN 38242Phone+1 731-642-1220
Education & Training
Beijing Medical UniversityClass of 1991
Certifications & Licensure
TN State Medical License 2023 - 2025
Publications & Presentations
PubMed
- 8 citationsTP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.Cheng Xu, Heng Liu, Christopher J. Pirozzi, Lee H. Chen, Paula K. Greer
Acta Neuropathologica Communications. 2021-11-03 - 13 citationsDual role of allele-specific DNA hypermethylation within the TERT promoter in cancerDonghyun Lee, Martin Komosa, Sumedha Sudhaman, Ricardo Leão, Cindy Zhang
The Journal of Clinical Investigation. 2021-11-01 - 180 citationsThe implications of IDH mutations for cancer development and therapyChristopher J. Pirozzi, Hai Yan
Nature Reviews. Clinical Oncology. 2021-06-15
Journal Articles
- The Genomic Landscape of TERT Promoter Wildtype-IDH Wildtype GlioblastomaDaniel B. Loriaux, Darel D. Bigner, Fausto J. Rodriguez, Hai Yan, Bil H. Diplas, Henry S. Friedman, Roger E. McLendon, Nature
Press Mentions
REMD Biotherapeutics Announces Positive Top-Line Results in a Phase 2 Program of Lead Product Candidate Volagidemab in Patients with Type 1 DiabetesJune 28th, 2021- REMD Biotherapeutics Completes Enrollment and Announces Top-Line Results of a Phase 2 Clinical Study of Volagidemab (REMD-477) in Patients with Type 1 DiabetesJanuary 7th, 2021
- Lessons in History, Hope and Living with Lynch Syndrome from the “Daughter of Family G”August 26th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
